DIABETIC FOOT ULCERS TREATMENT MARKET ANALYSIS

Market News

Global Diabetic Foot Ulcers Treatment Market: Key Developments

In June 2023, VIVEX Biologics, Inc., a leading regenerative medicine company specializing in the development of naturally sourced treatments, announced that the Centers for Medicare and Medicaid Services (CMS) had assigned a Q-code for its CYGNUS Dual amniotic allograft product. The providers can begin using the CYGNUS Dual code Q4282 under the Healthcare Common Procedure Coding System (HCPCS). The CYGNUS dual product will become more readily available to patients who can use it, especially those with chronic wounds, diabetic foot ulcers, and other difficult-to-heal wounds, thanks to the HCPCS Q-code.

For instance, in May 2022, PolarityTE, Inc., a biotechnology company, announced the enrollment of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational use of treatment of Wagner grade 2 diabetic foot ulcers (DFUs), entitled “Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE,” or “COVER DFUs.”

Global Diabetic Foot Ulcers Treatment Market: Key Trends

New diabetic foot ulcers treatment clinics

The new clinics provide specialized care and advanced treatment options for patients with diabetic foot ulcers, improving their overall quality of life. Additionally, the increasing prevalence of diabetes worldwide has contributed to the growing demand for diabetic foot ulcer treatments and, subsequently, the expansion of the market. For instance, on August 19, 2023, Apollo Hospitals Group announced the launch of Apollo Diabetic Foot Clinics to provide preventive and therapeutic care in the treatment of the diabetic foot. The specialized clinics would help in the early identification of signs of a diabetic foot and prevent complications through proper diabetes management. The major aim would be to reduce the risk of ulcers, infections, and lower limb amputations due to infections arising from diabetes.